Organon Q2 2021 revenue $1.6B, net income $431M; declares inaugural $0.28 quarterly dividend

Organon & Co.

2021-Q2 EPS reported $3.25 revenue$3,101,000,000

Q2 2021 revenue $1,595M (+5% as-reported; -1% ex-FX); Women's Health +19%, Biosimilars +43%, Established Brands -4%.
Net income from cont. ops. $431M ($1.70 diluted EPS); adjusted net income $437M ($1.72 adj. diluted EPS); adjusted EBITDA $627M.
Board declares quarterly dividend of $0.28/share, payable Sept 13, 2021 to holders of record Aug 23, 2021.
Full-year 2021 guidance affirmed: revenue $6.1B-$6.4B, adjusted EBITDA margin 36%-38%, interest ~$400M.
Cash and equivalents $730M, debt $9,348M, net debt $8,618M as of June 30, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.